Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis
Status:
Terminated
Trial end date:
2009-12-12
Target enrollment:
Participant gender:
Summary
This study will involve the use of a new compound, SB-656933. Accumulation of inflammatory
white blood cells (mostly polymorphonuclear neutrophils)in the gut (colon) may be
contributing to the pathology of ulcerative colitis. It has been shown that SB-656933 reduces
polymorphonuclear neutrophils (PMN) accumulation in pre-clinical models of colitis.
99m-Tc-HMPAO scintigraphy is a imaging technique which will be used in this study to observe
the effect of SB656933 on the migration of PMN to inflamed tissue.